To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.8035433.
The past three decades have seen a quadruple rise in the number of people affected by diabetes mellitus worldwide, with the disease being the ninth major cause of mortality. Type 2 diabetes mellitus (T2DM) often remains undiagnosed for several years due to its asymptomatic nature during the initial stages. In India, 70% of diagnosed diabetes cases remain uncontrolled. Current guidelines endorse the initiation of insulin early in the course of the disease, specifically in patients with HbA1c > 10%, as the use of oral agents alone is unlikely to achieve glycemic targets. Early insulin initiation and optimization of glycemic control using insulin titration algorithms and patient empowerment can facilitate the effective management of uncontrolled diabetes. Early glucose control has sustained benefits in people with diabetes. However, insulin initiation, dose adjustment, and the need to repeatedly assess blood glucose levels are often perplexing for both physicians and patients, and there are misconceptions and concerns regarding its use. Hence, an early transition to insulin and ideal intensification of treatment may aid in delaying the onset of diabetes complications. This opinion statement was formulated by an expert panel on the basis of existing guidelines, clinical experience, and economic and cultural contexts. The statement stresses the timely and appropriate use of basal insulin in T2DM. It focuses on the seven vital Ts—treatment initiation, timing of administration, transportation and storage, technique of administration, targets for titration, tablets, and tools for monitoring.
World Health Organization. Global report on diabetes. 2016. http://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf;jsessionid=6424E5BEBB8E8DA1225A8A1462B1768A?sequence=1. Accessed 14 Jan 2018.
International Diabetes Federation. IDF diabetes atlas. 8th ed. 2017. https://www.idf.org/e-library/epidemiology-research/diabetes-atlas.html. Accessed 15 Jan 2018.
Madhu SV, Saboo B, Makkar BM, et al. RSSDI clinical practice recommendations for management of type 2 diabetes mellitus, 2015. Int J Diabetes Dev Crit. 2015;35(1):1–71. CrossRef
Kanungo S, Mahapatra T, Bhowmik K, et al. Diabetes scenario in a backward rural district population of India and need for restructuring of health care delivery services. Epidemiol. 2016;6(2):1. CrossRef
Ray S, Pramanik S, Ghosh S. Combination treatment of oral agents and insulin in type 2 diabetes: a narrative review. Int J Diabetes Metab Disord. 2016;1(1):1–7.
ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28. CrossRef
American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2002;25(Suppl 1):s28–32.
American Diabetes Association. Standards of medical care in diabetes—2018. http://care.diabetesjournals.org/content/diacare/suppl/2017/12/08/41Supplement_1.DC1/DC_41_S1_Combined.pdf. Accessed 15 Jan 2018.
American Diabetes Association. Standards of medical care in diabetes—2019 (abridged for primary care providers). Clin Diabetes. 2019;37(1):11.
Moses CA, Seshiah V, Sahay BK, et al. Baseline results indicate poor glycemic control and delay in initiation and optimization of insulin therapy: results from the Improving Management Practices and Clinical Outcomes in Type 2 Diabetes Study. Indian J Endocrinol Metab. 2012;16(Suppl 2):S432.
Wangnoo SK, Maji D, Das AK, et al. Barriers and solutions to diabetes management: an Indian perspective. Indian J Endocrinol Metabol. 2013;17(4):594. CrossRef
Unnikrishnan IR, Anjana RM, Mohan V. Importance of controlling diabetes early—the concept of metabolic memory, legacy effect and the case for early insulinisation. J Assoc Phys Indian. 2011;59(Suppl):8–12.
Kalra S, Ved J, Baruah MP. Diabetes destiny in our hands: achieving metabolic karma. Indian J Endocr Metab. 2017;21(3):482. CrossRef
Kalra S, Gupta Y, Unnikrishnan AG. Flexibility in insulin prescription. Indian J Endocr Metab. 2016;20(3):408. CrossRef
Standl E, Maxeiner S, Raptis S, Karimi-Anderesi Z, Schweitzer MA. Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care. 2005;28(2):419–20. PubMedCrossRef
Meneghini L, Atkin SL, Gough SC, et al. NN1250-3668 (BEGIN FLEX) Trial Investigators. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36(4):858–64. PubMedPubMedCentralCrossRef
Thomas N, Jeyaraman K, Asha HS, Velavan J. A practice guide to diabetes mellitus. 6th ed. New Delhi: Jaypee Brothers Medical Publishers Ltd.; 2012. https://books.google.co.in/books?id=FKnvtY88WN8C&pg=PA101&lpg=PA101&dq=transportation+of+insulin+vials+in+India&source=bl&ots=2VXj0933PT&sig=NbRXRucNRn2St_ALhFDJtWlemMc&hl=en&sa=X&ved=0ahUKEwiR0ryMnpHZAhXMpo8KHfzQAGcQ6AEIbjAO#v=onepage&q=transportation%20of%20insulin%20vials%20in%20India&f=false. Accessed 7 Feb 2018.
Donner T. Insulin—pharmacology, therapeutic regimens and principles of intensive insulin therapy. Baltimore, MD: The Johns Hopkins University School of Medicine; 2015. https://www.ncbi.nlm.nih.gov/books/NBK278938/.
ADEA. Clinical guiding principles for subcutaneous injection technique. 2015. https://www.adea.com.au/wp-content/uploads/2015/11/Injection-Technique-Final-digital-version2.pdf. Accessed 8 Feb 2018.
Tandon N, Kalra S, Balhara YP, et al. Forum for injection technique and therapy expert recommendations, India: the Indian recommendations for best practice in insulin injection technique, 2017. Indian J Endocr Metab. 2017;21(4):600. CrossRef
Shah S, Sharma SK, Singh P, et al. Consensus evidence-based guidelines for insulin initiation, optimization and continuation in type 2 diabetes mellitus. J Assoc Physicians India. 2014;62(7 Suppl):49–54. PubMed
Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med. 2006;23(7):736–42. PubMedCrossRef
Davies MJ, Boelle-Le Corfec EM, Bonnemaire M, et al. Self-titration with insulin glargine 300 or 100 U/mL has improved efficacy vs. physician-led titration—comparison of the TAKE-CONTROL, AT. LANTUS, and ATLAS studies in people with type 2 diabetes (T2DM). Poster presented at ADA 2018. Diabetes. 2018;67(Suppl 1). CrossRef
Kelwade J, Sethi B. Efficacy of glimepiride as an add-on therapy to insulin in patients with high insulin requirement. Poster presented at IDF Congress 2017; 2017 Dec 4–8; Abu Dhabi, UAE.
Austin MM. The two skill sets of self-monitoring of blood glucose education: the operational and the interpretive. Diabetes Spectr. 2013;26(2):83–90. CrossRef
Kalra S, Khandelwal D. The Hypoglycaemia Awareness Questionnaire (HAQ). J Pak Med Assoc. 2018;68(2):322–3.
Woodfield J. Diabetes PA and the 10 best diabetes apps available. http://www.diabetes.co.uk/blog/2015/07/diabetes-pa-and-the-ten-best-diabetes-apps-available/. Accessed 28 April 2018.
Doyle A. The Best diabetes apps of 2016. http://www.healthline.com/health/diabetes/top-iphone-android-apps#4. Accessed 28 April 2018.
- BE-SMART (Basal Early Strategies to Maximize HbA1c Reduction with Oral Therapy): Expert Opinion
A. K. Das
Pradip Krishna Shrestha
Tint Swe Latt
Than Than Aye
A. G. Unnikrishnan
Md. Faruqe Pathan
Silver K. Bahendeka
Abdurezak Ahmed Abdela
- Springer Healthcare
Research, treatment and education of diabetes and related disorders
Print ISSN: 1869-6953
Elektronische ISSN: 1869-6961
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II